Beta-Adrenergic Modulation of Drug Cue Reactivity

Recruiting now · Phase 4 · Has a placebo group

Conditions studied: Tobacco Use Disorder, Nicotine Dependence, Cigarette Smoking

In brief

This study is designed to investigate the effects of a beta-adrenergic antagonist (Propranolol; 40 mg IR) and nicotine patch (14 mg) administered alone and in combination on neurobiological and behavioral responses to smoking cues in ongoing cigarette smokers. This is a basic experimental study in humans and participants will not take these medications for an extended period or make a cessation attempt as part of their involvement in this research project.

Key facts

Study ID

NCT05587361

Run by

University of Oklahoma

People needed

80

Starts

2024-11-26

Expected to finish

2027-03-31

Last updated by the study team

2026-04-28

Who can join

Age: 21 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Generally healthy
• Age 21-60
• Right-handed using a three-item scale
• Daily smoker of ≥ 5 cigarettes/day delivering 0.5 mg nicotine (FTC)
• Smoking regularly for ≥ 1 year, with stable smoking for the past 6 months
• Afternoon expired Carbon Monoxide (CO) concentration ≥ 6 ppm and/or morning urinary cotinine >100 ng/ml
• Must identity at least 4 different smoking locations used in a typical week
• Able to read and understand English

You may not qualify if…

• Inability to attend all required sessions
• Significant health problems that would preclude active participation
• Presence of conditions that would make MRI unsafe (e.g. pacemaker) or (e.g. weight and body shape)
• Current use of psychoactive medications/drugs as indicated by self-report or urine screen
• Positive breath alcohol concentration
• Pregnant, breastfeeding, or planning to become pregnant during the course of the study (females)
• Problems with vision that cannot be corrected with contacts or glasses
• Current regular use of smokeless tobacco, smoking cessation medications, or other nicotine containing products (e.g. electronic cigarettes)
• Current use of beta-adrenergic medications (e.g. beta-blockers) or other blood pressure medications
• Systolic blood pressure < 90 mmHg or diastolic blood pressure < 60 mmHg (sitting or standing)
• Abnormal EKG
• Presence of severe anemia
• Presence of electrolyte imbalance that could impact blood pressure
• Presence of any other contraindications for propranolol or nicotine patch (e.g. cardiovascular disease, bronchial asthma, prior allergic reactions, diabetes)

Where it is running

• Hardesty Center for Clinical Research and Neuroscience — Tulsa, Oklahoma, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.